Genetic polymorphism of vascular endothelial growth factor: Impact on progression of IgA nephropathy

被引:11
作者
Chow, KM [1 ]
Szeto, CC
Lai, FMM
Poon, P
Wong, TYH
Li, PKT
机构
[1] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China
[2] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, Shatin, Hong Kong, Peoples R China
关键词
vascular endothelial growth factor (VEGF); polymorphism; immunoglobulin A (IgA) nephropathy; histological grading; disease progression;
D O I
10.1080/08860220500461203
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background . Vascular endothelial growth factor (VEGF) plays a pivotal role in the capillary endothelial cell growth and proliferation and has known effects on glomerular microvascular permeability. Because certain VEGF polymorphisms are correlated with alterations in VEGF expression, we hypothesized that VEGF genetic polymorphisms may affect the renal survival and progression of primary IgA nephropathy. Methods . The study population consisted of 195 biopsy-proven IgA nephropathy patients at our center between 1984 and 2004. VEGF genotype polymorphism at -2578 positions was determined from peripheral blood leukocytes DNA using polymerase chain reaction methodologies. The primary end point was kidney survival as measured by the time interval from renal biopsy to end-stage renal disease or the requirement of renal replacement therapy. Results . In total, we studied 119 women (61%) and 76 men (39%), with a mean age of 35 10 yr at the time of renal biopsy. Observed genotype frequency was 55.6%, 38.8%, and 5.1% for CC, CA, and AA genotypes respectively. Baseline characteristics did not differ significantly between three genotype groups for patient age, sex, prevalence of hypertension, degree of proteinuria, initial serum creatinine concentration, and the histological grading. After a median follow-up period of 11 yr, doubling of the baseline serum creatinine occurred in 107 of them; 99 patients reached end-stage renal disease requiring renal replacement therapy with a median renal survival of 88 months. The kidney survival in the CC genotype subgroup was similar to that of the CA/AA genotype subgroup during the first 2 yr but became worse than the latter thereafter (log-rank test P = 0.023). The kidney survival rates at the end of 6 yr were 76.8% in the CA genotype, 67.0% in the CC, and 50.0% in the AA genotype groups. Unadjusted hazard ratio of developing end-stage renal disease was 2.65 (95% CI, 1.16 to 6.06) for the CC group as compared to the CA/AA group. The influence of VEGF genotype upon renal survival, however, was not significant after multivariate Cox regression analysis. Conclusion . Our preliminary results raise the concern that the CC genotype of the VEGF promoter at -2578 position might be associated with increased risk of renal progression in patients with IgA nephropathy.
引用
收藏
页码:15 / 20
页数:6
相关论文
共 21 条
[1]   Aberrantly glycosylated IgA molecules downregulate the synthesis and secretion of vascular endothelial growth factor in human mesangial cells [J].
Amore, A ;
Conti, G ;
Cirina, P ;
Peruzzi, L ;
Alpa, M ;
Bussolino, F ;
Coppo, R .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 36 (06) :1242-1252
[2]   A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes [J].
Awata, T ;
Inoue, K ;
Kurihara, S ;
Ohkubo, T ;
Watanabe, M ;
Inukai, K ;
Inoue, I ;
Katayama, S .
DIABETES, 2002, 51 (05) :1635-1639
[3]   Novel polymorphisms in the promoter and 5′ UTR regions of the human vascular endothelial growth factor gene [J].
Brogan, IJ ;
Khan, N ;
Isaac, K ;
Hutchinson, JA ;
Pravica, V ;
Hutchinson, IV .
HUMAN IMMUNOLOGY, 1999, 60 (12) :1245-1249
[4]  
Cipriani R, 2004, DIABETES NUTR METAB, V17, P90
[5]   The role of VEGF-A in glomerular development and function [J].
Eremina, V ;
Quaggin, SE .
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2004, 13 (01) :9-15
[6]   Down-regulation of vascular endothelial growth factor in renal cell carcinoma cells by glucocorticoids [J].
Iwai, A ;
Fujii, Y ;
Kawakami, S ;
Takazawa, R ;
Kageyama, Y ;
Yoshida, MA ;
Kihara , K .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2004, 226 (1-2) :11-17
[7]   Possible role of VEGF in the progression of kidney disease in streptozotocin (STZ)-induced diabetic rats: Effects of an ACE inhibitor and an angiotensin II receptor antagonist [J].
Kakizawa, H ;
Itoh, Y ;
Imamura, S ;
Matsumoto, T ;
Ishiwata, Y ;
Ono, Y ;
Yamamoto, K ;
Kato, T ;
Hayakawa, N ;
Oda, N ;
Goto, Y ;
Nagasaka, A ;
Senda, T ;
Itoh, M .
HORMONE AND METABOLIC RESEARCH, 2004, 36 (07) :458-464
[8]   Vascular endothelial growth factor: a new player in the pathogenesis of renal fibrosis [J].
Kang, DH ;
Johnson, RJ .
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2003, 12 (01) :43-49
[9]  
Kang DH, 2001, J AM SOC NEPHROL, V12, P1448, DOI 10.1681/ASN.V1271448
[10]   Vascular endothelial growth factor expression and glomerular endothelial cell loss in the remnant kidney model [J].
Kelly, DJ ;
Hepper, C ;
Wu, LL ;
Cox, AJ ;
Gilbert, RE .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2003, 18 (07) :1286-1292